Accessibility Menu
ImmuCell logo

ImmuCell(NASDAQ) ICCC

Current Price$11.29
Market Cap$101.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)+1,020%
5 Year+9%
1 Year+63%
1 Month+14%
ImmuCell last closing stock price
MetricPriceDate
Last closeUSD 11.132026-07-22
ImmuCell stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.73%USD 10.732026-07-15
1 month+14.21%USD 9.752026-06-22
3 month+39.13%USD 8.002026-04-23
Year to date+80.98%USD 6.152025-12-31
1 year+62.96%USD 6.832025-07-22
3 year+106.88%USD 5.382023-07-21
5 year+8.69%USD 10.242021-07-23
Since inception+1,019.5%USD 1.001992-05-01

ImmuCell Financials at a Glance

Market Cap

$101.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$29.93M

Net Income (TTM)

-$545.40K

EPS (TTM)

-$0.06

P/E Ratio

-185.96

Dividend

$0.00

Beta (Volatility)

0.21 (Low)

Price

$11.29

Volume

286

Open

$11.24

Previous Close

$11.29

Daily Range

$11.24 - $11.30

52-Week Range

$4.52 - $12.10

Estimated Earnings Date

Aug 13, 2026

ICCC News

featured-earnings-leadership-highlights.png

ImmuCell Q2 Profit Jumps as Margins Rise

Motley Fool Markets TeamAug 15, 2025
Foolcom-Featured.png

ImmuCell Posts 18% Gain in Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ImmuCell

ImmuCell helps dairy and beef farmers keep newborn calves healthy. Its main products protect calves from common diseases and support udder health in cows. These solutions help farmers reduce losses and improve productivity.

Udderly Practical: Products and Services

  • First Defense line (99% of revenue): Oral products for newborn calves to prevent scours, a common digestive disease.
  • Tri-Shield First Defense: Provides immediate immunity to calves against E. coli, coronavirus, and rotavirus.
  • Dual-Force First Defense: Whey protein supplement for calf nutrition and feed markets.
  • California Mastitis Test (1% of revenue): Simple test to detect udder infections in dairy cows by measuring cell counts in milk.
  • Re-Tain (in development): Non-antibiotic treatment for early-stage udder infections in lactating cows.

Growth Spurts: Expansion and Strategic Moves

  • Expanded First Defense production capacity from $16.5M (2019) to $30M (2025), with plans for $40M.
  • Launched new functional feed platform for large dairies and calf ranches in 2025.
  • Formed research partnership with Mayo Clinic in 2024 to explore Nisin for human health.
  • Entered select international markets, with international sales up 170% year-over-year in Q2 2025.
  • Invested in new facilities and freeze-drying equipment to support growth since 2019.

Why ImmuCell Stands Out (No Bull)

ImmuCell relies on unique colostrum and Nisin technologies to address key cattle health challenges. Its products are distributed mainly through animal health distributors, with a strong focus on North America. The company’s production investments have reduced order backlogs and supported steady revenue growth.

Five Things You Need to Know

  • Q2 2025 revenue was $6.4 million, up 18% from Q2 2024.
  • First Defense products made up 99% of Q2 2025 sales.
  • Gross margin reached 44% in Q2 2025, up from 22% in Q2 2024.
  • International sales were 24% of Q2 2025 revenue, up 170% year-over-year.
  • Two distributors accounted for 81% of Q2 2025 sales.

Bottom Line

ImmuCell has grown by focusing on practical cattle health solutions and expanding production. Its reliance on a few products and customers shapes both its opportunities and risks.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

73

CEO

Olivier te Boekhorst

Website

www.immucell.com

Headquarters

Portland, ME 04103, US

ICCC Financials

Key Financial Metrics (TTM)

Gross Margin

42.59%

Operating Margin

8.35%

Net Income Margin

-1.82%

Return on Equity

-1.88%

Return on Capital

4.10%

Return on Assets

-1.24%

Earnings Yield

-0.54%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$101.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

9.05M

Volume

286

Avg. Volume

30.29K

Financials (TTM)

Gross Profit

$12.75M

Operating Income

$2.50M

EBITDA

$2.39M

Operating Cash Flow

$4.47M

Capital Expenditure

-$1.10M

Free Cash Flow

$3.38M

Cash & ST Invst.

$6.81M

Total Debt

$12.78M

ImmuCell Performance Analysis

ImmuCell annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 18,567,962-3.5%
20232023-12-31USD 17,471,669-5.9%
20242024-12-31USD 26,493,16951.6%
20252025-12-31USD 27,644,1744.3%
ImmuCell sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-20.1%
Q32025-09-30-14.6%
Q42025-12-3138.5%
Q12026-03-3135.8%
ImmuCell annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.323026.2%
20232023-12-31USD -0.75131.5%
20242024-12-31USD -0.26-64.6%
20252025-12-31USD -0.12-56.4%
ImmuCell sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-65.3%
Q32025-09-30-127.7%
Q42025-12-31-1913.0%
Q12026-03-31167.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$10.36M

+28.4%

Gross Profit

$4.66M

+38.9%

Gross Margin

44.97%

N/A

Market Cap

$101.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.39M

N/A

Employees

73

N/A

Net Income

$1.94M

+34.2%

EBITDA

$2.58M

+15.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.81M

+48.1%

Total Debt

$12.78M

-12.8%

Accounts Receivable

$2.69M

-20.8%

Inventory

$8.67M

+17.9%

Long Term Debt

$11.06M

-13.3%

Short Term Debt

$1.72M

-9.5%

Return on Assets

-1.24%

N/A

Return on Invested Capital

6.22%

N/A

Free Cash Flow

$3.40M

+172.8%

Operating Cash Flow

$3.57M

+127.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EQEquillium, Inc.
$2.76+4.94%
CUECue Biopharma, Inc.
$34.20+2.21%
FBIOFortress Biotech, Inc.
$3.55+0.57%
NRXPNRx Pharmaceuticals, Inc.
$4.48+0.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.00+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%
SOFISoFi Technologies
$17.07-0.03%

Questions About ICCC

What is the current price of ImmuCell?

ImmuCell is trading at $11.29 per share.

What is the 52-week range for ImmuCell?

Over the past 52 weeks, ImmuCell has traded between $4.52 and $12.10.

How much debt does ImmuCell have?

As of the most recent reporting period, ImmuCell reported total debt of $12.78M.

How much cash does ImmuCell have on hand?

ImmuCell reported $6.81M in cash and cash equivalents in its most recent financial results.

What is ImmuCell’s dividend yield?

ImmuCell does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services